Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...
Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...
Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...
The two companies will use ALT-B4 to develop a subcutaneous version of the antibody-drug conjugate (ADC) cancer treatment ...
Hurricane Rafael is swirling over the Gulf of Mexico where it’s expected to break apart after plowing through Cuba, knocking ...
Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...
The brother of the acting mayor of Buffalo has died in a fall from a tree stand while hunting. Acting Mayor Chris Scanlon said in a statement Thursday that his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback